



MEDIPHAGE

BIOCEUTICALS

661 University Ave., Suite 1300
MaRS Centre, West Tower
Toronto, Ontario, M5G 0B7

PRESS RELEASE

FOR IMMEDIATE RELEASE
April 1st, 2019

CONTACT: Farah
Business Development Associate
farah.elzarkout@mediphage.ca

Mediphage Bioceuticals, Inc. Appoints Dr. Nafiseh Nafissi as VP of Research and Development

Toronto, Ontario – Mediphage Bioceuticals, Inc., a genetic medicine company developing **safe, effective, and accessible** therapeutics to unlock the power of *personalized and redosable* genetic medicine, announced that it appointed Dr. Nafiseh Nafissi as its new Vice President of Research and Development.

Dr. Nafiseh Nafissi specializes in molecular biology and pharmaceutical science, and brings over 15 years of hands-on expertise in biotechnology, genome engineering, and gene therapy in both academic and industrial settings. Dr. Nafissi is the co-inventor of Mediphage's novel ministring DNA (msDNA) platform technology and has been leading Mediphage's research and development, manufacturing, therapeutic development, and partnerships since joining the company in Fall 2018.

Nafiseh holds degrees from the University of Waterloo, ON, Canada (M.Sc. and PhD) and University of Tehran, Iran (B.Sc.). She has received a special certificate of Drug Development and Effectiveness by CIHR and Certificate of University Teaching from UW. Prior to joining Mediphage Bioceuticals, she completed her post-doctoral fellowship at the Universities of Toronto and Waterloo focusing on developing non-viral neuroprotective genetic medicine for glaucoma. Given her background and extensive experience, Mediphage is excited to have Dr. Nafissi lead research and development at Mediphage Bioceuticals and move forward the commercialization of msDNA technology.

About Mediphage

Mediphage Bioceuticals is a precision genetic medicine company with a mission to eradicate suffering from a wide range of chronic diseases through revolutionary therapeutics. The Toronto-based company, founded in January 2016 as a spin-off from the University of Waterloo, uses proprietary *E. Coli*-based manufacturing platforms to generate safe, effective and redosable gene delivery vectors called ministring DNA or msDNA. Mediphage's proprietary msDNA platform is an efficient, customizable, durable, and highly scalable, non-viral gene delivery vector which confers application to *in vivo* and *ex vivo* gene or cell therapies. Mediphage is focusing its internal efforts on developing a therapeutic for Stargardt Disease, an ocular inherited condition caused by a mutation of the large *ABCA4* gene. As a platform technology, msDNA has the potential for broad applicability to various gene or cell therapy and gene editing categories including T-cell and B-cell applications, DNA vaccines, iPSC, CRISPR and rAAV production.